更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向胆管癌肿瘤微环境：精准医学的机遇
英文原题：Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine.
查看英文原题
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
系统性治疗（如化疗和靶向治疗）对局部晚期不可切除和转移性胆管癌（CCA）患者的疗效有限，总生存期不足一年。肿瘤微环境（TME）代表围绕肿瘤的生态系统，包括免疫细胞、成纤维细胞、内皮细胞以及多种可溶性因子。CCA的TME以丰富的促结缔组织增生性间质为特征，表现出高度异质性，并在癌症的发生和进展中发挥核心作用。越来越多的证据表明，可以将TME作为靶点，与细胞毒性化疗或靶向治疗等其他治疗方式联合使用，为具有协同效应的联合策略开辟了道路。在此，我们描述了CCA TME的组成部分——如癌症相关成纤维细胞和其他具有关键重要性的细胞——及其最相关的相互作用，重点关注开发有效抗癌治疗的临床前依据。
展开英文摘要原文
Systemic treatments (e. g. , chemotherapy and targeted therapies) have limited efficacy for patients with locally advanced - unresectable - and metastatic cholangiocarcinoma (CCA), with an overall survival of less than a year. Tumor microenvironment (TME) represents the ecosystem surrounding the tumor which comprises immune cells, fibroblasts, endothelial cells, and a wide range of soluble factors.
CCA TME is characterized by an abundant desmoplastic stroma, exhibits a high heterogeneity and it plays a central role in cancer onset and progression. There is growing evidence suggesting that it is possible to target TME in association with other treatment modalities, such as cytotoxic chemotherapy or targeted therapies, paving the way to possible combination strategies with a synergistic effect.
Herein, we describe the components of CCA TME - such as cancer-associated fibroblasts and other cells of pivotal importance - with their most relevant interactions, focusing on the preclinical rationale for the development of effective anticancer treatments.
论文信息
- 作者
- Carloni R、Rizzo A、Ricci AD、Federico AD、De Luca R、Guven DC、Yalcin S、Brandi G
- 第一作者单位
- Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Via Giuseppe Massarenti, 9, Bologna 40138, Italy; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15, Bologna 40138, Italy.Italy
- 通讯作者单位
- Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari 70124, Italy. Electronic address: rizzo.alessandro179@gmail.com.Italy
- 文献类型
- 综述
- 期刊
- Translational oncology2022 Nov
- 原文标识
- PubMed 35977458 · DOI 10.1016/j.tranon.2022.101514
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →